0001193125-26-228179
SEC filingMindWalk Holdings Corp. released a report identifying over 20 drug candidates from its antibody discovery work, with 10 currently in active Phase 1-3 clinical trials.
MindWalk Holdings Corp. (NASDAQ: HYFT) issued a press release on May 18, 2026, detailing a systematic report identifying over 20 drug candidates originating from its antibody discovery work. Ten of these are in active clinical trials (Phase 1-3) across oncology, immunology, neurology, and infectious disease. The company emphasizes that its wet-lab discovery capabilities, combined with its HYFT/LensAI biological intelligence infrastructure, have consistently produced clinical-stage assets for partners. The report aims to demonstrate MindWalk's scientific track record and the compounding value of its AI platform, which integrates biological pattern recognition with wet-lab workflows. No financial guidance or material agreements were disclosed.